We're harnessing the natural process of autophagy to design powerful new medicines for a broad range of diseases. Our Twitter guidelines: https://bit.ly/2I9HDI3
Location: United States, Massachusetts, Cambridge
Total raised: $200.5M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | The Column... | thecolumng... |
| - | Ono Ventur... | onoventure... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 15.11.2022 | Series C | $46M | - |
| 15.11.2022 | Series C | $46M | - |
| 14.09.2020 | Series B | $50M | - |
| 03.05.2018 | Series A | $58.5M | - |
Mentions in press and media 16
| Date | Title | Description |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 15.11.2022 | Casma Therapeutics Raises $46.0M in Series C Funding | Casma Therapeutics, a Cambridge, MA-based biotechnology company, raised $46.0M in Series C funding. The round was led by Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Euclidean Capital, Mirae Asset, and Ono Venture Investment... |
| 15.11.2022 | Casma Therapeutics Inks $46M Series C Funding | CAMBRIDGE, MA, Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46 million. >> Click here for more funding ... |
| 14.09.2020 | Casma Therapeutics Raises $50 Million In Series B | Casma Therapeutics — a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines — announced it has raised $50 million in Series B funding Casma Therapeutics — a biotechnology company harnessing autophagy ... |
| 10.09.2020 | Casma Therapeutics nabs $50M series B to find treatments using the cell's garbage disposal | Fierce 15 winner Casma Therapeutics has bagged $50 million as it looks to kick on with its early work in muscular dystrophy. After a couple of years’ incubation at Third Rock Ventures, Casma launched back in May 2018 with $58.5 million to c... |
| 10.09.2020 | Casma Therapeutics Completes $50M Series B Funding | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a $50 million Series B financing. The financing, ... |
| 10.09.2020 | Casma Therapeutics Raises $50M in Series B Financing | Casma Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company, completed a $50m Series B financing. The round, led by The Column Group (TCG), adds new investors Eventide Asset Management, LLC and Schroder Adveq, as well as other ... |
| 10.09.2020 | Casma Therapeutics Completes $50M Series B Funding | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a $50 million Series B financing. The financing, ... |
| 10.09.2020 | Casma Therapeutics nabs $50M series B to find treatments using the cell's garbage disposal W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Fierce 15 winner Casma Therapeutics has bagged $50 million as it looks to kick on with its early work in muscular dystrophy. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for a... |
| 04.11.2018 | Life sciences VC investment trends similar to tech, but there are differences | There are some similar trends in the life sciences market versus technology overall, but there are some differences in underlying drivers, said Menlo Park Ventures life sciences investor Greg Yap, in an email. “Round sizes have continued to... |
Show more